Navigation Links
LifeCycle Pharma Announces Positive Phase I Clinical Results for,its Transplantation Product Candidate, LCP-Tacro

Heads into US Phase II Clinical Trials for Organ Transplantation

HORSHOLM, Denmark, May 31, 2007 /PRNewswire-FirstCall/ -- LifeCycle Pharma announces positive Phase I clinical results for its transplantation product candidate, LCP-Tacro - Heads into US Phase II clinical trials for organ transplantation.

Today LifeCycle Pharma A/S (OMX:LCP) announces positive results from its Phase I clinical trial program of LCP-Tacro, a proprietary, once-daily tacrolimus tablet.

A series of Phase I trials, involving more than 150 healthy volunteers demonstrate that LCP-Tacro:

- Has a once-daily profile.

- Delivers consistently higher bioavailability of about 50% compared to Prograf(R).

- Reduces peak levels (Cmax) and reduces peak (Cmax) / trough (Cmin) fluctuation compared to Prograf(R).

"The once-daily profile and significant increase in bioavailability, compared to Prograf(R), that has been demonstrated for our LCP-Tacro product candidate in an extensive Phase I program is encouraging, and provides the foundation to quickly advance it into Phase II trials for organ transplantation, said Dr. Flemming Ornskov, President and CEO of LifeCycle Pharma". LifeCycle Pharma's long-term strategy is to concentrate on and commit significant resources to the development of a number of product candidates for organ transplantation as it moves towards becoming a fully integrated specialty pharmaceutical company" added Dr. Ornskov.

About the studies:

LifeCycle Pharma has conducted a series of Phase I studies in more than 150 healthy volunteers to demonstrate the profile of LCP-Tacro under single-dose and multi-dose (steady-state) conditions. In addition to this, dose-linearity, food-effect and diurnal pharmacokinetic studies have been completed.

About transplantation:

In order to prevent the patient's immune system from rejecting the transplanted organ, immunosuppression t
'"/>




Page: 1 2 3

Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
(Date:7/30/2014)... PARIS , July 30, 2014  Regeneron Pharmaceuticals, ... SAN and NYSE: SNY ) today announced ... in people with hypercholesterolemia met their primary efficacy endpoint ... lipoprotein cholesterol (LDL-C) at 24 weeks compared to placebo ... targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
(Date:7/30/2014)... and NEW YORK , July ... a developer of new products for oncology supportive care, ... ® , has been featured in an article on ... Symptoms in Head and Neck Cancers."  Dr. Steve ... insight on the growing demand seen in the oncology ...
(Date:7/30/2014)... July 30, 2014   Bluegrass Vascular Technologies ... innovating lifesaving devices and methods for vascular access, ... Series A financing, which was led by ... deal will allow Bluegrass Vascular to obtain CE ... enhance manufacturing capabilities, and proceed with US regulatory ...
Breaking Medicine Technology:Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8Access Pharmaceuticals Featured On OncLive.com 2Access Pharmaceuticals Featured On OncLive.com 3Bluegrass Vascular Technologies Raises $4.5M Series A Financing Led By Targeted Technology Funds 2
... July 27, 2011 Pharmaceutics International, Inc. (Pii), a ... it has added hot melt extrusion (HME) to its ... has purchased a 16mm and an 18mm Leistritz twin ... feasibility studies, using just a few grams of active ...
... Pharmaceuticals, Inc., announced today that the company has ... Angel Investors. The company is using the capital ... orphan receptor (ROR) modulators targeting TH17 T-lymphocytes for ... arthritis, multiple sclerosis, psoriasis and COPD. ...
Cached Medicine Technology:Pharmaceutics International, Inc. (Pii) Expands Drug Formulation and Manufacturing Capabilities with Hot Melt Extrusion Technology 2Visionary Pharmaceuticals, Inc., Announces Initial Seed Round Investments and the Launch of TH17 Autoimmune Disease Research Activities 2
(Date:7/30/2014)... Texas (PRWEB) July 30, 2014 “North ... key market data on the North America Contrast Media ... US dollars, and volume (in units) and average price ...     CT Injectors ,     Interventional Cardiology/Angio Injectors and ... (or contrast agent) is a substance used to enhance ...
(Date:7/30/2014)... for Vedic Studies (WAVES) conference is coming to Fairfield, ... 31 through Sunday, August 3. To watch the main ... the first time such a large and diverse group ... to explore the relevance of ancient Vedic knowledge in ... states of consciousness, and reflections on the various Vedic ...
(Date:7/30/2014)... Naomi Fried, PhD, and Alexis ... Directors of the American Telemedicine Association (ATA). ... has a mission to promote professional, ethical and ... information technology. , “Both Naomi Fried and Alexis ... expertise and are well known experts in their ...
(Date:7/30/2014)... 2014 The global digital pathology market was ... expected to grow at a CAGR of 11.8%, to reach ... digital pathology is growing and is expected to continue to ... scanners and image analysis software enable pathologists to be efficient ... In 2013, the North American market was valued at $128.9 ...
(Date:7/30/2014)... to suffer from depression as school-age children and young ... times more likely to suffer from the condition in ... depressed at very young ages, according to researchers at ... Their study is published in the July issue of ... the same old bad news about depression; it is ...
Breaking Medicine News(10 mins):Health News:Contrast Media Injectors Market in North America (US, Canada, Mexico) to 2020 Report Available at MarketOptimizer.org 2Health News:Contrast Media Injectors Market in North America (US, Canada, Mexico) to 2020 Report Available at MarketOptimizer.org 3Health News:Contrast Media Injectors Market in North America (US, Canada, Mexico) to 2020 Report Available at MarketOptimizer.org 4Health News:Vedic living in a modern world: International conference at Maharishi University 2Health News:Vedic living in a modern world: International conference at Maharishi University 3Health News:American Telemedicine Association Welcomes Two New Members to the Board of Directors 2Health News:Global Digital Pathology Market To See 11.8% CAGR to 2018 Says a New Research Report Available at ReportsnReports.com 2Health News:Global Digital Pathology Market To See 11.8% CAGR to 2018 Says a New Research Report Available at ReportsnReports.com 3Health News:Global Digital Pathology Market To See 11.8% CAGR to 2018 Says a New Research Report Available at ReportsnReports.com 4Health News:Global Digital Pathology Market To See 11.8% CAGR to 2018 Says a New Research Report Available at ReportsnReports.com 5Health News:Many depressed preschoolers still suffer in later school years 2Health News:Many depressed preschoolers still suffer in later school years 3
... ... movies for presentations, demonstrations and training. Version 7.5 introduces TrakMouse™, a new technology that ... , ... July 9, 2009 -- NetPlay Software releases Instant Demo v7.5 , a Windows ...
... Hollywood impact radiation perception? Can we treat cancer with ... the radiation exposure our astronauts receive during space travel ... and other questions will be addressed at the 54th ... will take place July 13-16, 2009 in Minneapolis, MN, ...
... ... change the law regarding personal injury accidents, New York personal injury lawyer David Perecman weighs ... New York, New ... Authority (MTA) spends millions to pay for damages caused to riders., , , , ,Unfortunately ...
... MedClean Technologies, Inc. (OTC Bulletin Board: MCLN) announced today ... the Company,s existing Common Stock Purchase Warrants with Initial Exercise ... Warrants") for newly issued Common Stock Purchase Warrants with a ... one-half the original number of shares of our common stock, ...
... TROIS-RIVIERES, Quebec, July 8 The Narconon drug rehab program ... with drug related charges due to their addiction. "You ... drug addiction, and just one day gets caught by police ... representative of Narconon Trois-Rivieres. "This is an all too ...
... Today, the American Hospital Association, Federation of American Hospitals ... White House and Senate Finance Chairman Max Baucus (D-MT) ... Cost savings is an important goal, supported by Physician ... owned hospitals. As always, physician hospitals will shoulder their ...
Cached Medicine News:Health News:Instant Demo Screen Recorder Now With TrakMouse™ Technology 2Health News:Health Physics Society 54th Annual Meeting 2Health News:As Lawsuits Hit the MTA, Personal Injury Lawyers Consider How Much is Too Much, or Too Little 2Health News:As Lawsuits Hit the MTA, Personal Injury Lawyers Consider How Much is Too Much, or Too Little 3Health News:MedClean Technologies Announces Results of Private Exchange Offer 2Health News:Drug Crimes in Canada Cause Continuing Problems for Small Communities 2Health News:Physician Hospitals of America Charges: Hospital Associations Bargain Away $155 Billion in Medicare Funding in Attempt to Destroy Physician Hospitals 2Health News:Physician Hospitals of America Charges: Hospital Associations Bargain Away $155 Billion in Medicare Funding in Attempt to Destroy Physician Hospitals 3
... incorporate a layered design unique in the ... to prevent stray electrosurgical burns along the ... failure or capacitive coupling; a well-documented patient ... all AEM Instruments provides a neutral return ...
... The 5mm AEM Laparoscopic Instruments incorporate a ... Instruments are shielded and monitored to prevent ... the instrument caused by insulation failure or ... The protective shield built into all AEM ...
... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...
The Auto Suture™ ExtraHand™ balloon retractor is designed to be used during open surgery, gasless endoscopy, as well as endoscopy with gas insufflation....
Medicine Products: